The global isocitrate dehydrogenase (IDH) inhibitors market garnered a market value of USD 1.7 Billion in 2022 and is expected to accumulate a market value of USD 39.16 Billion by registering a CAGR of 33% in the forecast period 2023 to 2033.
The market's growth can be attributed to the rising occurrence of IDH-mutated cancers, such as acute myeloid leukemia (AML) and cholangiocarcinoma, which are frequently managed using IDH inhibitors. The market for isocitrate dehydrogenase (IDH) inhibitors registered a CAGR of 18% in the historical period 2018 to 2022
Isocitrate dehydrogenase (IDH) inhibitors are a class of drugs that target the mutated form of the IDH enzyme found in certain types of cancer cells. These drugs work by blocking the activity of the mutated IDH enzyme, which is involved in the development and progression of cancer.
The IDH inhibitors market refers to the pharmaceutical industry's production and sale of these drugs. This market has grown significantly in recent years, with the approval of several IDH inhibitors by regulatory agencies such as the FDA and the EMA.
IDH inhibitors are primarily used in the treatment of acute myeloid leukemia (AML) and other types of cancers, such as cholangiocarcinoma and glioma, that have mutations in the IDH gene. The market for IDH inhibitors is expected to continue to grow as more research is conducted on the use of these drugs in the treatment of cancer.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 2.26 Billion |
| Anticipated Forecast Value (2033) | USD 39.16 Billion |
| Projected Growth Rate (2023 to 2033) | 33% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Isocitrate dehydrogenase (IDH) inhibitors reflected a value of 18% during the historical period, 2018 to 2022.
The market is expected to be driven by several factors, including the growing incidence of cancer, the increasing adoption of personalized medicine, and the development of targeted therapies for cancer treatment. The availability of favorable regulatory frameworks for the approval of IDH inhibitors is also expected to drive growth in the market.
In terms of geography, North America has been the largest market for IDH inhibitors, followed by Europe and Asia-Pacific. However, the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period, driven by the growing prevalence of cancer in the region and increasing investment in healthcare infrastructure.
Overall, the IDH inhibitors market is expected to continue to grow over the forecast period, driven by increasing demand for more effective and targeted cancer treatments.
Thus, the market for Isocitrate dehydrogenase (IDH) inhibitors is expected to register a CAGR of 33% in the forecast period 2023 to 2033.
Increasing incidence of cancer driving the growth of IDH inhibitors market
The incidence of cancer is on the rise globally, and IDH inhibitors are a promising new class of drugs that offer targeted therapy for specific types of cancers. IDH mutations are found in a high percentage of certain types of cancers, such as AML, cholangiocarcinoma, and glioma. This provides a significant opportunity for the development and use of IDH inhibitors as a treatment option.
Advances in drug discovery and development techniques have enabled the identification and development of targeted therapies, such as IDH inhibitors, with greater efficacy and fewer side effects.
The regulatory environment for IDH inhibitors has been favorable, with several drugs already approved by regulatory agencies such as the FDA and EMA. This has encouraged investment in research and development of these drugs.
IDH inhibitors represent a targeted therapy that can be tailored to the specific genetic makeup of an individual's cancer. As demand for personalized medicine grows, the market for IDH inhibitors is likely to expand.
Development in inhibitors shaping the landscape for IDH inhibitors market
IDH1 inhibitors: These inhibitors specifically target the mutated form of the IDH1 enzyme, which is found in certain types of cancers such as cholangiocarcinoma and glioma. Examples of IDH1 inhibitors include ivosidenib (Tibsovo) and enasidenib (Idhifa), which have been approved by the FDA for the treatment of AML with IDH1 mutations.
IDH2 inhibitors: These inhibitors specifically target the mutated form of the IDH2 enzyme, which is found in certain types of cancers such as AML. Examples of IDH2 inhibitors include agios (AG-221), ivosidenib (Tibsovo), and enasidenib (Idhifa), which have been approved by the FDA for the treatment of AML with IDH2 mutations.
Principal Consultant
Limited patient population along with high drug development costs derailing market growth
IDH inhibitors are only effective in patients with specific genetic mutations in the IDH gene, which limits the eligible patient population for these drugs. This means that the market potential for IDH inhibitors is relatively small compared to other cancer therapies.
Developing targeted therapies such as IDH inhibitors can be expensive, and the costs associated with research and development may be passed on to consumers in the form of high drug prices. The market for cancer therapies is highly competitive, and there are several established treatments available for many types of cancers. IDH inhibitors face competition from other targeted therapies as well as traditional chemotherapy and radiation treatments.
Patients may develop resistance to IDH inhibitors over time, which can limit the effectiveness of these drugs in the long term. Like all drugs, IDH inhibitors can cause adverse effects, and patients may experience side effects such as nausea, vomiting, and fatigue. Managing these side effects can be challenging for both patients and healthcare providers. All these factors are hampering the market growth of IDH inhibitors market.
Presence of key market players bolstering the market growth for IDH inhibitors market in North America
The North America Isocitrate Dehydrogenase (IDH) inhibitors market is one of the largest markets for these drugs globally. The market is primarily driven by the high prevalence of cancer in the region and the increasing use of targeted therapies for cancer treatment.
In North America, the United States is the largest market for IDH inhibitors, followed by Canada. The FDA has approved several IDH inhibitors for the treatment of AML and other types of cancers, which has contributed to the growth of the market.
Moreover, the presence of key players in the region, such as Agios Pharmaceuticals, Celgene Corporation, and Daiichi Sankyo, has also fueled the growth of the market. These companies have invested heavily in research and development to bring new IDH inhibitors to the market. Thus, North America is expected to possess 46% market share for IDH inhibitors market in 2023.
Growing incidence of cancer in Europe boosting market growth of ISH inhibitors
The incidence of cancer is on the rise in Europe, and this is driving demand for more effective cancer treatments such as IDH inhibitors. Pharmaceutical companies are investing heavily in research and development of IDH inhibitors to develop more effective and targeted therapies for cancer treatment.
The European Medicines Agency (EMA) has granted accelerated approval to several IDH inhibitors, which has created a favorable regulatory environment for the development and commercialization of these drugs.
IDH inhibitors are a type of personalized medicine that targets specific mutations in cancer cells, and as awareness about personalized medicine grows, demand for IDH inhibitors is also increasing.
There is a strong pipeline of IDH inhibitors in Europe, with several drugs in various stages of clinical trials. This is expected to drive growth in the market in the coming years. Thus, Europe is expected to possess 43% market share for IDH inhibitors market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Fewer side effects of oral IDH inhibitors making them easier for consumption
By route of administration, the IDH inhibitors market is segmented into Oral, Parenteral and Subcutaneous
Oral Isocitrate Dehydrogenase (IDH) inhibitors are one of the types of IDH inhibitors used in cancer therapy. Oral IDH inhibitors have certain advantages over other types of cancer therapies, such as chemotherapy, which is typically administered intravenously. Oral medications can be taken at home, and they may have fewer side effects than chemotherapy. Additionally, oral IDH inhibitors are often more targeted and may be more effective against cancer cells with specific IDH mutations.
Thus, by route of administration, oral IDH inhibitors is expected to possess 49% market share for IDH inhibitors market in 2023.
Key players in the isocitrate dehydrogenase (IDH) inhibitors market are Bayer, Agios Pharma, Daiichi Sankyo, Ohm Oncology, Celgene, Philogen S.p.A., Tragara, Aslan Pharmaceuticals, Pfizer, Inc. and Sun Pharmaceutical Industries Ltd.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 2.26 Billion |
| Market Value in 2033 | USD 39.16 Billion |
| Growth Rate | CAGR of 33% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Type, Molecule Type, Route of Administration, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Rest of Latin America, Germany, United Kingdom, France, Spain, Italy, Rest of Europe, India, Malaysia, Singapore, Thailand, Rest of South Asia, China, Japan, South Korea, Austria, New Zealand, GCC countries, South Africa, Israel, Rest of MEA |
| Key Companies Profiled | Bayer; Agios Pharma; Daiichi Sankyo; Ohm Oncology; Celgene; Philogen S.p.A.; Tragara; Aslan Pharmaceuticals; Pfizer, Inc.; Sun Pharmaceutical Industries Ltd. |
| Customization | Available Upon Request |
The global market is worth USD 2.26 billion in 2023.
The market is anticipated to thrive at a 33% CAGR from 2023 to 2033.
The market expanded at an 18% CAGR from 2018 to 2022.
Europe’s holds nearly 43% of the market share in 2023.
The oral IDH inhibitors segment leads, with 49% of the market share in 2023.
1. Executive Summary | Isocitrate Dehydrogenase (IDH) Inhibitors Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type 5.1. IDH1 Mutant Medullary Malignant Tumor 5.2. IDH2 Mutant Medullary Malignant Tumor 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Molecule Types 6.1. Monoclonal Antibody 6.2. Peptides 6.3. Small molecule 6.4. Others 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 7.1. Oral 7.2. Parenteral 7.3. Subcutaneous 7.4. Topical 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. South Asia 8.5. East Asia 8.6. Oceania 8.7. MEA 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. Bayer 18.2. Agios Pharma 18.3. Daiichi Sankyo 18.4. Ohm Oncology 18.5. Celgene 18.6. Philogen S.p.A. 18.7. Tragara 18.8. Aslan Pharmaceuticals 18.9. Pfizer, Inc. 18.10. Sun Pharmaceutical Industries Ltd. 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Isocitrate Dehydrogenase (IDH) Inhibitors Market
